How to Evaluate Indication Expansion Opportunities

Possibility is cheap

Indication expansion feels easy in the early conversation because possibility is cheap. If the mechanism works in one setting, it is always tempting to imagine where else it might work.

The hard part is that plausible biology, tractable development, open competitive space, and meaningful strategic upside rarely line up as neatly as the whiteboard suggests.

That is why indication expansion should be treated as a ranking problem with clear tradeoffs.

The most common mistakes

The first mistake is starting from market size. Large markets look attractive even when the biology, endpoints, or operational path make the opportunity a poor use of capital.

The second is over-weighting mechanistic plausibility. A decent biological story can still have a weak development path.

The third is refusing to cut. Teams sometimes keep six or seven options alive because they want to avoid the discomfort of ranking them honestly.

Step 1: define the asset as it really exists

Start by describing the actual asset as it exists today.

• What is the mechanism or platform?
• What safety, dosing, or biomarker constraints travel with it?
• What is already known about patient selection?
• What strategic constraints matter: timeline, geography, partner thesis, internal capability?

A weak asset frame produces a weak expansion discussion.

Step 2: score the dimensions separately

A useful workflow should force at least four dimensions into the open.

Biological plausibility

Is the mechanistic case genuinely strong, or merely suggestive?

Development reality

What do precedent, endpoints, enrollment burden, and operational complexity say about the path?

Competitive and IP pressure

Is the space open enough to reward another entrant?

Strategic weight

Would success here actually change the company, or is the opportunity more interesting than material?

Keeping these separate is what makes the tradeoffs legible.

Step 3: build a ranking frame the team can defend

The ranking model can stay simple, but it has to reflect the organization's actual priorities.

A platform company may tolerate more uncertainty if the strategic upside is large. A capital-constrained biotech may care more about time to differentiation. An investor-backed company may care most about the next value-inflecting event.

The goal is to make judgment inspectable.

Step 4: finish with a real recommendation

By the end of the workflow, leadership should be able to answer three questions:

1. Which indication should we prioritize now?
2. Why does it outrank the next two options?
3. What is the next piece of work required before full commitment?

If the output misses those questions, it is still exploratory rather than strategic.

Honesty is the hard part

Most bad indication-expansion work fails because the ranking was politically softened long before it was analytically defended. Teams keep too many options "interesting." They confuse plausible biology with usable strategy. They let commercial upside dominate development reality. Or they quietly assume that internal enthusiasm counts as evidence.

A strong workflow makes those distortions harder. It forces the team to separate scientific plausibility, development feasibility, competitive pressure, regulatory path, and economic weight long enough to show where the tradeoff actually lives.

How ARiDA helps

ARiDA handles this as a tiered workflow, which matters because the job changes shape as confidence increases. Indication Expansion Scan is for broad-universe triage. Indication Expansion Assessment is the deeper path when the team needs scoring, IP, regulatory path, and per-indication economics on a real shortlist. Indication Expansion Strategy is the board-grade version that turns the final choice into a development and investment roadmap.

That tiering is backed by specific lanes and artifacts. The database specialist handles target associations and competitive density. The literature specialist handles biology mapping and translational evidence. The regulatory specialist handles pathway scans. The patent specialist handles freedom-to-operate sketches. The valuation specialist handles initial and per-indication rNPV. The coding specialist turns those inputs into the scoring matrix, shortlist funnel, feasibility visuals, and ranked recommendations. The recommendation arrives at the end of a visible ranking process.

The discipline

The discipline in indication expansion is cutting intelligently under uncertainty.

A good workflow makes those cuts visible and leaves a record the team can revisit when the next piece of evidence arrives.